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Interference of Distinct Invariant Chain Regions with 
Superantigen Contact Area and  Antigenic  Peptide  Binding 
Groove  of HLA-DR' 
Anne B. Vogt,*  Lawrence J. Stern,+ Christine Amshoff,* Bernhard Dobberstein,* 
Gunter J. Hammerling,* and Harald Kropshofer** 
In the endoplasmic reticulum, MHC class II ab dimers  associate with the trimeric invariant chain (li), generating a nine-subunit 
(abli)3 complex. In the presence of li, the peptide binding groove is blocked, so that loading with self or antigenic peptides  can 
only occur after proteolytic removal of li in specialized post-Golgi compartments.  The class  11-associated invariant chain peptide 
region of li (about residues 81-1 04) is known to mediate binding to class II molecules  and blockade of the groove, but this does 
not exclude additional contact sites for li. Using a set of overlapping li peptides and recombinant soluble li, we demonstrate here 
that a large segment of Ii encompassing approximately residues 71 to 128 interacts with HLA-DR molecules. The N- and 
C-terminal regions of this Ii segment appear to bind outside the peptide groove to the contact area for the staphylococcal 
superantigen Staphylococcus aureus enterotoxin B on the a 1  domain. The core region of this segment (residues 95-108) 
prevents binding of antigenic peptides, probably by interaction with the peptide groove. Occupation of the groove with anti- 
genic peptides abolishes binding not only of the core region, but also that of  those Ii peptides that bind outside the groove. These 
findings suggest the existence of distinct conformational states of class II molecules, with Ii binding preferentially to one form. 
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T he MHC class 11-associated Ii3 is  a monomorphic type I1 transmembrane glycoprotein (1) that decisively influences the quality of Ag presentation by MHC  class I1 molecules 
(2). In the human system, the Ii gene encodes four polypeptide 
chains originating from differential splicing of the corresponding 
mRNA (3): the p33 form as well as the less abundant p41 form are 
both found without and with N-terminal extensions resulting in the 
p35 and the p43 forms (4, 5). Ii forms trimers in the ER and 
chaperones proper assembly of MHC a- and P-subunits, finally 
generating a nonameric complex (aPIi)3 (6). In the ER and during 
transport to endocytic compartments, aPIi complexes are not ac- 
cessible for peptides (7, 8). Furthermore, the assembly with Ii pre- 
vents aP dimers from association with polypeptides (9) or self- 
aggregation and inactivation (10, 11). A sorting signal in the 
cytoplasmic tail of li is responsible for efficient targeting of the 
nine-chain complex to post-Golgi compartments of the endocytic 
pathway (12,  13), where loading with self or antigenic peptides is 
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thought to occur (14-17). Stepwise proteolytic destruction of Ii, 
probably by members of the cathepsin family in vesicles of the 
endosomal-lysosomal system (18, 19), renders U P  dimers acces- 
sible for peptides derived from exogenous (20) and endogenous 
source proteins (21). ap:peptide complexes finally travel to the 
cell surface for subsequent presentation of peptides to T  cells (20). 
Biochemical studies on several naturally occurring fragments of 
Ii provided insight into the interaction of  Ii with class I1 molecules; 
a p25 Ii fragment was found to  be associated with CUP dimers. p25 
is  a soluble C-terminal Ii fragment (22) starting at position 98 of 
the p31 form of murine Ii (23) or at positions 91, 93, and 99 of 
the human p33 form (24). In contrast, treatment of cells with 
the cysteine protease inhibitor leupeptin leads to accumulation of 
a 22-kDa membrane-anchored N-terminal leupeptin-induced 
polypeptide (25) that trimerizes and is still engaged in a nonameric 
complex with MHC aP dimers (26). Both findings are in agree- 
ment with the results of systematic exon deletions and N- or C- 
terminal truncations of recombinant Ii, arguing that the membrane- 
proximal segment formed by amino acids 81 to 105 of exon 3 is 
crucial for interaction of  Ii with class I1 molecules (27-29), 
whereas the region between amino acids 163 and 183 seems to be 
essential for li trimerization (28). Further evidence underlining the 
capability of Ii region 81 to 105 to bind promiscuously to ab 
dimers comes from a nested set of li peptides spanning the 
above region. These CLIP (30) have been eluted from several 
murine (31, 32) and human class I1 molecules extracted from 
cells (21, 33, 34). They vary in length from 14 to 28 residues 
(21,  35) and  are  potent  inhibitors of antigenic peptide  binding to 
class I1 molecules (30, 36). 
It is still a matter of discussion, whether CLIP is a residual 
fragment of Ii proteolysis that remains bound to class I1 dimers 
or whether it rebinds after proteolysis of Ii. However, the finding 
that the number of ap:CLIP complexes is drastically reduced dur- 
ing transport from endosomes to the plasma membrane in B cells 
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(37) and the fact that purified ap:CLIP complexes cannot be dis- 
tinguished from those generated by limited in vitro proteolysis of 
afi:li complexes (34) favor the hypothesis that the CLIP segment 
of Ii associates with ap dimers during formation of the nonameric 
complex early after biosynthesis in the ER. In human wild-type B 
cells, a small but significant amount of olp dimers of various 
HLA-DR and -DQ isotypes is associated with CLIP under steady 
state conditions (21, 38), whereas in HLA-DM-negative Ag-pro- 
cessing mutants, such as T2 transfected with HLA-DR3, -DR4, or 
-DR11, CLIP was revealed to be the predominant self-peptide 
bound to DR molecules (30, 34). The presence of HLA-DM ap- 
pears to prevent the accumulation of @CLIP complexes and 
leads to proper peptide loading of class I1 molecules (39, 40). 
Thus, DM may be directly involved in the removal of CLIP, at 
least in the HLA-DR-associated Ag presentation pathway (41,42). 
There are findings arguing that aP:CLIP as well as apI i  com- 
plexes behave differently from complexes with Ag-derived pep- 
tides. Ii fails to form SDS-stable complexes with afi dimers (43), 
and the same has been found for certain @CLIP  complexes (30, 
34). CLIP is selectively released at endosomal pH (34, 44-46), 
afl:CLIP complexes do not undergo time-dependent maturation 
(46), and single mutations outside the peptide binding groove of 
class I1 molecules prevent CLIP, but not antigenic peptide, binding 
(36). Conversely, other studies have shown that polymorphic res- 
idues of ab dimers are involved in CLIP binding comparable to 
their involvement in antigenic peptide binding (34, 47, 48). How- 
ever, it should be kept in mind that at present we can exclude 
neither different binding modes of CLIP  for different class I1 alleles 
nor the existence of more than one binding mode for CLIP for 
certain class I1 molecules. 
There exists evidence that class I1 molecules are flexible entities 
that can occur in different conformations (49, SO). For example, the 
recently described short-lived kinetic intermediates of @:peptide 
complexes (51-53) seem to bear alternative conformations com- 
pared with the long-lived complexes known from the crystal struc- 
ture of HLA-DRl (54). Therefore, the questions arise whether ab 
dimers complexed to Ii or the CLIP region are structurally different 
from mature class I1 molecules loaded with antigenic peptides and 
whether CLIP  cooperates with other Ii stretches for binding to c.0 
dimers. 
In the present study we addressed the question of whether, be- 
sides CLIP, other regions of  Ii would interact with class I1 mole- 
cules. Using a set of overlapping Ii-derived peptides and recom- 
binant Ii we demonstrate that regions flanking CLIP contribute to 
the interaction of DR ~$3 dimers with Ii. These regions appear to 
contact the a1 domain outside the peptide binding groove, as su- 
perantigen SEB interferes with their binding. Unexpectedly, anti- 
genic and, therefore, bona fide groove binding peptides were also 
found to inhibit those Ii peptides that bound to the SEB contact 
area outside the groove, suggesting the existence of two different 
class I1 conformations: one stabilized by Ii binding and another 
that is gradually formed in the presence of antigenic peptides ac- 
cording to principles of the induced fit model. 
Materials and Methods 
Cells 
EBV-transformed B-LCL  LD2B (HLA workshop no. 9083) was used as  a 
source for isolation of DR2. Cells were maintained in RPMI with HEPES 
(Life Technologies, Grand Island, NY) with 5% calf serum (Life Technol- 
ogies)  at  37°C using roller bottles. Spodopteru frugiperdu (Sf9) were main- 
tained at 27°C in Grace medium (Life Technologies) in the presence of 
10% FCS. For protein production, cells were grown in serum-free SF900 
medium (Life Technologies). Virus infection was performed as previously 
described (55). 
Table I. Dissociation equilibrium constant Kd of l i  peptides for 
binding to HLA-DR2 
Peptide  R sidues Sequence K, [nMl 
li61 61-78 
li71 71-88 
li81 81-98 
li90 90-1 08 
li95 9.5-1 08 
IilOl 101-.118 
til 1 1  1 1  1-128 
li121 121-138 
li131 131-148 
li141 141-1.58 
CLIP 81-105 
RLDKLTVTSQNLQLENLR 
NLQLENLRMKLPKPPKPV 
LPKPPKPVSKMRMATPLL 
KMRMATPLLMQALPMGALP 
TPLLMQALPMGALP 
ALPMGALPQGPMQNATKY 
PMQNATKYGNMTEDHVMH 
MTEDHVMHLLQNADPLKV 
QNADPLKVYPPLKGSFPE 
PLKGSFPENLTHLKNTME 
LPKPPKPVSKMRMATPLLMQALP~G 
>1 o6 
1,600 
3,000 
35  
280 
4,300 
6,800 
8011 0,800 
>1  Obd 
>1 o6 
23 
high affinity binding site. 
"The Scatchard  plot of li121 gave a biphasic curve, indicating a low and a 
Purification of DR2 
LD2B cells (5 X 10') were homogenized in hypotonic lysis buffer (20 mM 
Tris (pH 7.8) containing protease inhibitors (0.2 mM PMSF, 2.5 pgiml 
leupeptin, 5 pgiml pepstatin, and 5 pgiml chymostatin)). Cytosolic pro- 
teins were separated by differential centrifugation (500 X g, 4"C, 10 min; 
12,000 X g ,  4"C, 10 min; 140,000 X g, 4"C, 1 h). Pellets containing the 
membrane fractions were pooled and lysed with lysis buffer containing 1 %  
Nonidet P-40 for 1 h on ice, and nuclear material was removed by cen- 
trifugation at 500 X g for 10 min at 4°C. Further purification of the cell 
extract was performed by centrifugation for 10 min at 12,000 X g at 4°C 
and ultracentrifugation at 140,000 X g for 1 h at 4°C. DRap molecules 
were purified from the ce l l  extract using a column of mAb L243 (56) 
coupled to CNBr-activated Sepharose (Pharmacia, Piscataway, NJ) accord- 
ing to the manufacturer's protocol. Glycine coupled to Sepharose was used 
as a precolumn. The cell extract was passed over the glycine-Sepharose and 
L243 Sepharose columns for 16 h. The L243 column was extensively 
washed with 100 mM sodium phosphate, pH 8.0, and 0.5% Zwittergent-12, 
followed by 100 mM sodium phosphate (pH 8.0) and 0.1% Zwittergent-12, 
and eluted with 100 mM sodium phosphate (pH 11.0) and 0.1% Zwitter- 
gent-12. The eluted material was neutralized with 1 M HCI and concen- 
trated by ultrafiltration with a 20-kDa cut-off membrane (Sartorius, Got- 
tingen, Germany). Solubilized DR molecules were kept at 4°C and a 
concentration of about 0.5 mgiml. 
sDRl was obtained from Sf9 cells infected with baculovirus as previ- 
ously described (55). 
Purification of p25 
The p25 fragment of Ii was isolated from EBV-transformed B-LCL LD2B 
as described previously (24). 
Peptides 
The following peptides spanning the region between the transmembrane 
domain and the putative trimerization domain of Ii were used (sequences 
are given in Table I):  Ii-(61-78) (Ii61), Ii-(71-88) (Ii71), Ii-(81-98) (Ii81), 
Ii-(90-108) (Ii90), Ii-(95-108) (Ii95), Ii-(101-118) (IilOl), Ii-(lll-l28) 
( I i l l l ) ,  Iik(121-138) (IilZl), Ii-(131-148) (Ii131), and Ii-(141-158) 
(Ii141). Numbering is according to the p33 form of human Ii (5). 
In addition,  the following antigenic peptides were used: PKYVKQ 
105); HLVEALYLVCGERGFFYTPW INS-(10-30), bovine insulin 
P-chain; and PLKAEIAQRLEDV IM-(19-31). 
Peptides were synthesized on an AMs422 Multiple Peptide Syntheziser 
(Abimed, Langenfeld, Germany) using F-moc chemistry and purified by 
reverse phase HPLC. Purified peptides were analyzed by matrix-assisted 
laser desorption mass spectrometry and shown to be single species. N- 
terminal labeling with AMCA (Lambda, Graz, Austria) was performed as 
previously described (57). 
Peptide binding assay 
Peptide binding to DR2 and sDRl was measured by HPSEC, as previously 
described (58). Briefly, purified DR2 (200 nM) or sDRl(50 nM) molecules 
were coincubated with AMCA-labeled peptide (10 nM to 50 FM) in the 
absence or the presence of inhibitor molecules in 100 mM sodium phos- 
phate buffer (pH 6.0) and  0.1% Zwittergent-12 (Calbiochem, La Jolla, CA). 
NTLKLAT, HA-(307-319); PVVHFFKNIWRTPPPSQGY MBP-(85- 
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exon 1 j exon 2 : I exon3 exon 4 exon5 exon 6 i exon 7 FIGURE 1. The following peptides spanning 
the region  between  the  transmembrane  do- 
main (TM) and  the  putative  trimerization do- H2N 
main (TRIM) of l i  were  used:  114-78) (li611, 
li-(71-88) (li71), liL(81-98) (li811, IiL(90-108) 
(li90),  Ii495-108)  (li95), 1 i - U  01-1 18) (lil 011, % 
l iL(ll1-128)  ( l i l l l) ,  IiL(l21-138)  (li121), l i -  ” 
(131-148)  (li131),  and  Ii-(l41-158)  (li141). m 
Numbering is according to the  p33  form of h u -  “h 
man i i  (5). The  exon  borders of the I i  gene  are 
indicated (65). 
M COOH 
81 105 
@ma 
After incubation for 40  h at 37”C, HPSEC was performed on a Superdex 
75 HR 5/20 column (Pharmacia) equilibrated with 150 mM sodium phos- 
phate buffer (pH 6.0), 0.1% Zwittergent-12, and 15% acetonitrile. The 
column run-through passed through a F1080 fluorescence detector (Merck- 
Hitachi; excitation,  350 nm; emission, 450 nm) and a LAO01 UV detector 
(Merck-Hitachi, Darmstadt, Germany) set up in series. Signals were re- 
corded by a model D2500 integrator (Merck-Hitachi, Darmstadt, Ger- 
many). Peptide:DR complexes eluted after 2.5 min with an elution volume 
of 1.5 ml. K,, values were calculated from the slope of the Scatchard plots 
of bound/free peptide vs hound peptide. Inhibition was calculated from 
fluorescence signals in the absence (F,)  and the presence (F,) of inhibitor: 
% inhibition = (F, - FJIF,, X 100. 
Recombinant li 
The cDNA encoding the human Ii (p33 form) was obtained from the Ii 
expression vector IipSV51L (12) using the 820-bp fragment, which was 
flanked by the NurI site at the 5’ end and the Sac1 site at the 3’ end. This 
fragment and a double stranded synthetic oligonucleotide (TAT  GGA  TGA 
CCAGCGCGACCTTATCTCCAACAATGAGCAACTGCCCAT 
GCT GGG CCG G) were introduced into the pET3a vector using the NdeI 
and Sac1 site. The transmembrane region was deleted by removing the 
fragment from the Sac11 site to the PsrI site, thereby restoring the 3’ C- 
terminal coding  40 bp with a double stranded oligonucleotide (GGC CGG 
CTG GAC AAA CTG ACA  GTC  ACC  TCC  CAG AAC CTG CA). At the 
3’ end of the I i  coding region, a 6-His tail was introduced at the BstYI 
site using the oligonucleotide (GAT CTG GGC CCA GTC CCC ATG 
CAC CAC CAC CAC CAC CAC TGA GCT). The resulting plasmid 
pET3a.Ii.DTMR-His was used to express rIi in Escherichia coli (BL21). 
Expression of rli was induced by treatment with 0.4 mM IPTG for 1 h 
at 37°C. Bacterial pellets were obtained by centrifugation (5000 rpm, 5 
min, 4”C), resuspended in 50 mM Tris (pH 7.59, 1 mM EDTA, and 1 mM 
PMSF and disrupted by freezindthawing in liquid nitrogen. After the ad- 
dition of 200 pgiml lysozyme, the bacterial suspension was incubated for 
15 min  on ice. One-tenth volume of 5 M NaCl was added and incubated for 
an additional 15 min on ice. Bacterial extract was clarified by centrifuga- 
tion at 10,000 X g for 30 min at 4°C. After the addition of 2 mM MgCI, 
and 20 mM imidazole, the extract was loaded onto a NiZt/NTA column 
(Quiagen, Chatsworth, MA) and washed extensively with the following 
buffers: 10 column volumes of 50 mM Tris (pH 7 4 ,  20 mM imidazole, 
and 500 mM NaCI; 1 column volume of 1 M NaCI; and 20 mM HEPES 
(pH 7.5), YO mM KC1, and 2 mM  MgCI,. Elution was performed with 250 
mM imidazole. The eluted material was concentrated by ultrafiltration with 
a 10 kDa cut-off filter (Centriprep, Amicon, Danvers, MA) and further 
purified by ion exchange chromatography on a Mono S Sepharose column 
(Pharmacia). Elution was performed with a gradient from YO mM to 1 M 
KCI. rIi eluted with 200 to 300 mM KC1 and was stored at 4°C. 
Results 
Flanking regions of CLIP bind to DR molecules 
Previous studies using Ii deletion and truncation mutants have 
shown that the CLIP region encoded by exon 3 is essential for 
binding of Ii to class I1 molecules (27-29). As this  does not rule 
out additional  contact  sites,  a  series of overlapping  peptides  (main- 
ly 18-mers) was synthesized  spanning  the region between the 
transmembrane and the putative trimerization domain of Ii, resi- 
dues 61 to 158 (Fig. 1). Each Ii peptide was tagged at the N ter- 
minus with the  fluorescence  label AMCA and tested for binding to 
purified HLA-DR2 molecules  using HPSEC and  fluorescence  de- 
tection. The use of peptides to mimic the behavior of defined 
stretches of Ii seems to be a valid approach,  as the Stokes’  radius 
of Ii trimers suggests an extended  conformation  without  globular 
folding of Ii (3) .  
As shown in Table I, all Ii peptides  except Ii61, li131,  and Ii141 
were  found to bind to DR2, with peptides  Ii90 and Ii95  from the 
CLIP region displaying the highest affinities (Kd = -35 and 280 
nM, respectively). Ii71 and I i lOl  that overlap with the N- and 
C-terminals of the CLIP sequence,  respectively, bind with lower, 
but  significant, affinity (Kd = -1.6 and  4.3 pM). Binding of l i l l l  
and Ii121 together with the lack of binding of Ii131 suggest that 
residues 111 to about 128 contribute to Ii binding. Likewise, the 
twofold higher affinity of Ii71  compared  with Ii81 implies that at 
least some of amino acids 71 to 80 are also involved in binding. 
The Scatchard plot of Ii121  was  biphasic,  indicating  two  binding 
sites: one with low affinity (Kd = -10.8 pM) and the  other  with 
high affinity (Kd = -80 nM). Binding of the li-derived peptides 
was specific, as it was competed out by the respective unlabeled 
peptide, and no binding to purified HLA class I molecules was 
observed (data not shown). These data suggest that not only the 
CLIP region (residues 81-105), but also a larger segment of Ii 
ranging  from  approximately  positions 71 to 128, can interact with 
class I1 molecules. 
As class I1 molecules  are  peptide  receptors,  one might argue that 
all the Ii-derived peptides bind in the antigenic peptide binding 
groove  like  conventional  peptides. To address  this  possibility, DR2 
was  simultaneously  incubated  with different AMCA-labeled Ii 
peptides. Examples  are  presented in Figure 2a. Using  AMCA-Ii71 
under saturating concentrations, addition of the AMCA-labeled 
peptides Ii90, IilOl, and I i l l l  led to respective additive binding 
signals. Likewise, unlabeled Ii90, IilOl, and I i l l l  did not inhibit 
AMCA-Ii71 binding (data not shown), and coincubation of the 
three nonoverlapping labeled peptides Ii71, Ii90, and I i l l l  re- 
sulted in additive  fluorescence  signals,  but  there  was no additivity 
when  overlapping  peptides  such  as  Ii71  and  Ii81 or Ii71 and Ii61 
were  coincubated (Fig. 2a). Ii121  was an exception, as it displayed 
only partial additive  binding with Ii71. li121 appears  to bind to an 
additional site on MHC class I1 molecules,  which may be the pep- 
tide  binding  groove or part of it. This view is consistent with the 
observation that the  Scatchard  analysis resulted in two  distinct Kd 
values  for Ii121 (see Table I). Corresponding  results  for Ii peptide 
binding were obtained with sDRl molecules produced in insect 
cells  (Fig. 2b). sDRl is free of detectable  peptide (55) and,  there- 
fore,  represents  a  homogeneous  population.  Accordingly,  saturat- 
ing amounts of labeled  Ii71  led to 95% occupancy of sDRl (data 
not shown). Simultaneous binding of Ii71 with Ii90, IilOl, and 
IilOl, but not with Ii61,Ii81,  or Ii121  confirms the results  obtained 
with DR2 and  excludes the possibility that Ii  peptides bind to dis- 
tinct DR subpopulations. Together, these data indicate that the 
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FIGURE 2. Cobinding  of  li-derived peptides. a, DR2 (200 nM) was coincubated  with different AMCA-Ii peptides (5 pM) in the absence (hatched 
bars) and  the presence (black bars) of saturating concentrations  of  AMCA-li71 (50 pM) for 40 h in HPSEC binding assay. b, sDRl (50 nM) was 
coincubated with different AMCA-Ii peptides (5 pM) in the absence (hatched bars) and presence (black bars) of saturating concentrations of 
AMCA-ti71 (50 pM) for 40 h in HPSEC binding assay. 
nonoverlapping Ii peptides bind to distinct sites on aP dimers and 
rule out that all peptides bind in the groove. 
li-derived peptides reflect binding of intact li 
To determine whether the Ii-derived peptides mirror the behavior 
of the corresponding regions in the Ii polypeptide chain and bind 
to the respective contact sites, inhibition studies with human rIi 
lacking the transmembrane domain were performed. As depicted 
in Figure 3, coincubation of rIi  with  the respective AMCA-labeled 
Ii peptides in a 2: 1 molar ratio moderately reduced binding of Ii90 
and Ii95 and very efficiently reduced binding of the other Ii pep- 
tides, reflecting the different affinities of the respective Ii peptides 
for DR2 (Table I). At higher concentrations of rIi, binding of Ii90 
and Ii95 and also that of Ii121  were completely blocked (data not 
shown). rli was also able to prevent binding of AMCA-labeled 
antigenic peptides MBP-(85-105) from MBP and HA-(307-319) 
from HA (Fig. 3), but failed to block the control peptide INS-(10- 
30) from the bovine insulin B chain that has been suggested to 
occupy an alternative binding site  on class I1 molecules (P. Jensen, 
personal communication). Additional evidence for correct binding 
The Journal of Immunology 4761 
*? 80 ~ s 
x 
v 
y1 
.z 6 0  - 
FIGURE 3. Inhibition of l i  peptide  binding  by  rli. 2 
DR2 (200 nM) was incubated together with the in- 01 
dicated peptides in its AMCA-labeled  form (1 pM) in u 
the absence (black bars) or  the presence (cross- E 40 ~ 
hatched bars) of  rli (2 pM) and analyzed after 40 h in 
the HPSEC binding assay. 01 s. 
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FIGURE 4. Selective inhibition of li peptide binding by l i  fragment 
p25. Titration of the inhibition  by  p25 (2-20 pM) of AMCA-labeled 
peptides li81,  li95, CLIP-(81-105), MBP-(85-105),  and  HA-(307-31 9), 
1 p M  each, on DR2 (200 nM). p25 starts with Ala'"', as shown by 
Edman sequencing, and contains the complete C terminus of li. 
of the Ii peptides was derived from the C-terminal Ii fragment p25, 
which is found associated with class I1 molecules ex vivo and in 
vitro (22, 24). p25 was isolated from the EBV-transformed B cell 
line LD2B. Sequencing of p25 by Edman degradation showed that 
its N-terminal amino acid uniformly was Ala'"'. Thus, it shares the 
same N terminus with peptide IilOl. p25 selectively blocked bind- 
ing of Ii peptides Ii95 and CLIP-(81-105), which overlap with the 
p25 sequence, but did not inhibit binding of nonoverlapping Ii81 or 
antigenic peptides (Fig. 4). These data for p25 are in good agree- 
ment with the binding of Iil01, I i l l l ,  and Ii121, in qualitative and 
in quantitative terms. Taken together, the additive binding and the 
selective inhibition by rIi and p25 strongly indicate that the Ii- 
derived peptides are oriented on sDRl and DR2 molecules in the 
same way as the corresponding regions in intact Ii. 
li61  li71  li81  li90  li95 li101 lilll li121 li131  li 41 MBP HA INS 
AMCA-labeled peptides 
Interaction of  li segments with the SEB contact area 
For identification of the contact region of class I1 molecules for 
Ii-derived peptides we employed SEB.  The x-ray structural anal- 
ysis of the co-crystal of SEB with HLA-DR1 showed that SEB 
binds to the a1 domain of (YP dimers exclusively outside the 
groove without interference with peptide binding in the groove 
(59). The results shown in Figure 5 confirm that SEB does not 
prevent groove binding of antigenic peptides; neither AMCA- 
MBP-(85-105) nor AMCA-HA-(307-319) binding to DR2 (Fig. 
5a) or sDRl (Fig. 5b) was influenced by SEB, even at a 20-fold 
molar excess of SEB (data not shown). In contrast, a twofold molar 
excess of SEB strongly or moderately blocked binding of all Ii 
peptides except Ii95 (Fig. 5, a and b). Ii95 was not inhibited even 
at high SEB concentrations (see inset, Fig. 5a). Only in the case of 
IilOl and I i l l l  were allelic differences in SEB inhibition ob- 
served; both peptides were efficiently inhibited by SEB on sDRl 
(Fig. 5b), but only moderately on DR2 molecules (Fig. 5a). Inhi- 
bition of CUP-(81-105) binding by SEB followed competitive 
kinetics, suggesting that both molecules competed for the same site 
(46). Together, these data imply that regions covering about amino 
acids 71 to 90 and 109 to 128 interact with sites outside the peptide 
binding groove on the SEB contact area on the a1 domain of DR 
molecules. The exact boundaries of these segments are not clear 
from these studies. 
fnterference with antigenic  peptide binding 
It is known that CLIP and antigenic peptides interfere with each 
other's binding. We addressed the question of which of the Ii- 
derived peptides would block antigenic peptides and vice versa. 
When AMCA-labeled Ii peptides were incubated for  48  h in the 
presence of antigenic peptide, it was observed on both sDRl and 
DR2 that all Ii peptides were inhibited by antigenic peptide (Fig. 
6, u and c) .  The inhibition was dose dependent, as 50 pM MBP- 
(85-105) (50-fold excess) was more efficient than 2 pM (twofold 
molar excess) of the same peptide. In addition, the inhibition was 
time dependent, as very little blockade was observed after 2  h of 
incubation (data not shown). The interference of groove binding 
peptides with those Ii peptides binding to the SEB contact area 
outside the groove (Ii71 and I i l l l ;  Fig. 5 )  suggests different con- 
formational states of DR molecules. Further evidence for at least 
two alternative conformations was obtained when the reverse ex- 
periment was performed, namely inhibition of labeled antigenic 
peptides by unlabeled Ii peptides. After 48-h coincubation, only 
Ii90 and Iil21 (the peptide with the exceptional behavior; Table I) 
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FIGURE 5. Selective inhibition of l i  pep- 
tide  binding by SEB. a, Binding of the  indi- 
cated AMCA-labeled li peptides (1 pM) to 
DR2 (200 nM) in the absence or the pres- 
ence of SEB (2 FM) was analyzed  by HPSEC. 
Inset, Titration of the inhibition  by SEB 
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AMCA-labeled peptides 
were able to decrease AMCA-MBP-(85-105) binding to DR2 and 
AMCA-HA-(307-319) binding to sDR1, but not the other Ii pep- 
tides despite a 100-fold molar excess (Fig. 6,  b and d). The same 
amount of unlabeled MBP-(85-105)  or  HA-(307-319) led to quan- 
titative inhibition on DR2 and sDR1, respectively. This result dem- 
onstrates that the region Ii90-108 of CLIP is essential for efficient 
inhibition of antigenic peptide binding to DR1 and DR2 molecules. 
However, when the kinetics of inhibition were studied in more 
detail, we found that after short time incubation, antigenic peptide 
binding was also inhibited by Ii71, which binds outside the groove 
(Fig. 7). In the absence of Ii71, AMCA-HA-(307-319) attained 
half-maximal binding to sDRl after a f,,2 of approximately 4 h, 
reaching maximal binding after approximately 30 h (Fig. 7a). Un- 
der steady state conditions, about 85% of sDRl molecules were 
occupied by AMCA-HA-(307-319). However, in the presence of 
Ii71, the strong inhibition observed after 1 h (75%) gradually de- 
creased to 15% after 48 h. The time dependency of inhibition, as 
calculated from the data in Figure 7a, is depicted in Figure 7b. This 
effect is not due to different kinetics of AMCA-HA and AMCA- 
Ii71 binding, as the two association curves are almost superimpos- 
able (Fig. 7a). For ligands and inhibitors binding to the same site 
and stabilizing the same conformation of ~$3 dimers, the inhibitory 
potential is expected to be independent of the incubation time. 
Indeed, when the groove binding influenza matrix peptide IM- 
(19-31) was used as an inhibitor for AMCA-HA-(307-319), no 
time dependency of the inhibitory potential was observed. To- 
gether, these data indicate distinct binding sites for Ii71 and anti- 
genic peptides and the existence of at least two distinct conforma- 
tional states of aP dimers. 
Discussion 
Previous studies using recombinant Ii truncation and deletion vari- 
ants provided indirect evidence that the CLIP region (residues 81- 
104) is essential for promiscuous binding to class I1 molecules. 
Especially residues 96 to 104 were found to mediate binding to 
DR1 (28), and residues 90 to 104 were sufficient for inhibition of 
loading of DR1, DR2, and DR3 with antigenic peptides (33, 46, 
48). The present study shows that Ii peptide Ii90 (residues 90-108) 
binds not only to DR1 and DR2, but also to peptides from the 
flanking regions (amino acids 71-89 and 109-128), albeit with 
lower affinity (Table I and Fig. 8). The moderate or low affinity of 
these flanking regions might explain why they were not found in 
studies involving coprecipitation of certain Ii truncation constructs 
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with aP dimers.  Several  complementary  findings  strongly  suggest 
that the Ii peptides  spanning  the region 71  to 128 bound  to  the  DR 
molecule in the same manner  as in the  context of the intact Ii. I )  
Nonoverlapping  Ii  peptides  displayed  additive  binding and did not 
compete with each other, whereas overlapping peptides did not 
bind simultaneously (Fig. 2). 2)  Soluble rIi prevented binding of 
all Ii peptides (Fig. 3). 3) The C-terminal Ii fragment p25 inter- 
fered only with those Ii peptides that overlap with the p25 se- 
quence  (Fig. 4). Thus, it is likely that in the  context of whole  Ii, not 
only CLIP but  also  the  flanking  regions  contribute  to the assembly 
of aP:Ii complexes. 
Inhibition by the superantigen SEB provided  information on the 
respective contact sites of Ii peptides on the DR1 and DR2 aP 
dimers  and  suggested that the flanking  regions  covering  residues 
71 to 94 and 109 to 128 interact  with  the SEB contact area on the 
a1 domain. These results  are  schematically  compiled in Figure 8. 
It should be kept in mind that determination of the precise  bound- 
aries of the  respective  segments  awaits further studies. For exam- 
ple, it is not clear whether all residues of the segment 71 to 81 
interact with the DR2 molecules,  but the slightly  higher affinity of 
Ii71 compared  with  that of IiSl (Table I) indicates  a  contribution 
of at least some residues.  Our SEB data  seem to be in contrast to 
the earlier finding that Ii expression on the cell surface does not 
inhibit SEB binding to D R l t  cells (60), but in agreement  with 
our  data,  inhibition of SEB  binding to cells  by  rIi  was  recently 
reported (61). 
The only  peptide  not affected by SEB  was Ii95  (Fig.  5).  How- 
ever, the Ii95 sequence is contained in Ii90, which is a powerful 
competitor of antigenic  peptide  binding on both  DR  alleles  (Fig. 6, 
b and d). The most  straightforward  explanation  for  both  findings is 
that  peptide  Ii90  binds  directly  to  the  peptide  binding  groove. This 
would be consistent  with the recent suggestion  that CLIP binds  to 
class I1 molecules  like  conventional  antigenic  peptides, with Met"' 
of CLIP  being part of a  supermotif and an important  anchor res- 
idue for pocket PI of the DR groove (47, 48). Indeed, the x-ray 
structure of a DR3:CLIP complex visualizes residues Pros7 to 
Ala"" ' In the binding  groove,  with  Met"'  being one of the  anchor 
residues (P., Gosh, M. Amaya, E. Mellins, and D. C. Wiley,  per- 
sonal communication). With Ii90 being located in the groove, it 
has to be explained how inhibition of Ii90 by SEB from outside  the 
groove  is  accomplished  (Fig. 5).  Two possibilities come to  mind. 
Assuming that the crystal  data  describing  binding of CLIP to DR3 
can  also be extended  to DR1 and DR2 molecules  with Lys"' and 
Met"' lying in the groove, then SEB binding outside the groove 
could be accompanied by small structural changes inside  the  pep- 
tide  groove  that  would  prevent  binding of Ii90, but not binding of 
Ii95 or the  antigenic  peptides HA and MBP. This model would be 
tides (1 pM) in the absence (black bars) or the presence of 2 pM 
M&P-(85-105)  (hatched bars) or 50 pM MBP-(85-105) (white bars) for 
48 h in HPSEC binding assay. 0, Inhibition of AMCA-MBP 85-105 
binding  by li peptides on  DR2. DR2 (200  nM) was coincubated  with 
AMCA-MBP-(85-105) (1 00 nM)  in the absence and the presence of the 
indicated li peptides (1 0 pM) or MBP-(85-105) (1 0 pM) for 48 h in the 
HPSEC binding assay. c, Inhibition of li peptide  binding  by  HA-(307- 
319) on s D R l .  sDRl (50 nM) was incubated with various AMCA-la- 
beled l i  peptides (1 pM) in the absence (black bars) or the presence of 
50 pM HA-(307-319) (white bars) for 48 h in the HPSEC binding 
assay. d, Inhibition of AMCA-HA-(307-319)  binding  by  li peptides on 
- 
*HA 
sDRl. s D R l  (50 nM) was coincubated with AMCA-HA-(307-319) 
FIGURE 6. Interference of l i  peptides with antigenic peptides on DR (1 00 nM) in the absence and the presence of the indicated Ii pep- 
molecules. a, Inhibition of l i  peptide  binding  by  MBP-(85-105)  on  tides ( I O  pM) or HA-(307-319) (10 pM) for 48 h in the HPSEC 
DR2. DR2 (200 nM) was incubated with various AMCA-labeled li pep- binding assay. 
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FIGURE 7. Kinetics of the inhibitory  effect of li71 on  AMCA-HA- 
(307-31 9) binding  to sDRl . a, sDRl (50 nM) was coincubated with 50 
nM AMCA-HA-(307-319) (O), 10 FM AMCA-li71 ( O ) ,  50 nM AMCA- 
HA-(307-319) in the presence of 10 pM Ii71 (VI or with 50 nM 
AMCA-HA-(307-319) in the presence of 10 p M  IM-(19-31) (. and 
analyzed by HPSEC after  the  indicated  incubation  times. b, Inhibitory 
capacity of li71 (V) or IM 19-31 (.) on  AMCA-HA-(307-319) (50 nM) 
binding to sDRl at different time points, calculated from values in 
Figure 7a. 
consistent with the hypothesis that some, but not all, groove bind- 
ing peptides might interfere with SEB binding (62). Alternatively, 
our data raise the possibility that Ii90 binds differently to DR1 and 
DR2 than described for DR3:crystal. On DR1 and DR2 molecules 
residues 90 to 94 of Ii90 might reach out of the groove, thereby 
directly competing with SEB for an overlapping binding area on 
top or outside of the binding cleft.  The latter model is consistent 
with distinct binding modes for antigenic peptides and Ii90, as 
suggested by the observation that antigenic peptides preclude the 
binding of Ii71 and I i l l l  (Fig. 6), whereas Ii90 displayed simul- 
taneous binding to both Ii peptides (Fig. 2). 
The observation that antigenic peptides were able to prevent not 
only binding of Ii90, but, after long-term incubation, also binding 
of those Ii peptides whose contact sites are outside the groove on 
the SEB contact area, such as  Ii71 and I i l l l  (Fig. 6), suggests the 
existence of at least two conformational states of class I1 mole- 
cules. One state (designated here as S2)  is described by the con- 
formation we know from the crystallographic studies with HLA- 
DR1 (63); it is stabilized by groove binding peptides that bind with 
slow on and off rates and excludes simultaneous stable binding of 
Ii peptides under steady state conditions (Fig. 7). The other con- 
formational state (Sl) is compatible with Ii binding and charac- 
terized by fast on and off rates of its ligands explaining the fast on 
rate of Ii in vivo (64) and the fast off-rate of CLIP on DR1  (44), 
DR3, DR4, and DRl l  (34). Since antigenic peptides can compete 
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FIGURE 8. Functional domains of invariant chain. 
with Ii peptides binding to the SEB contact area (e.g., Ii71; Fig. 7), 
they appear to be able to bind to the S1 state (or  a similar inter- 
mediate conformation). With time, however, antigenic peptides 
(but not Ii peptides) induce a gradual shift toward the stable S2 
state. Such a model would explain that inhibition of AMCA-HA by 
Ii71 decreases with time (Fig. 7), and inhibition of AMCA-Ii71 by 
antigenic peptides increases with time (data not shown). This 
model is consistent with previous kinetic studies also suggesting 
distinct conformational states of class I1 molecules (51-53). Ac- 
cording to this, initial binding of antigenic peptide by a fast on rate 
and low affinity is followed by a conformational change resulting 
in a slow on rate  and  high  aftinity.  Such a maturation of DR2 mole- 
cules could  not  be  observed  when CLIP was used as a ligand (46). 
In conclusion, the present study adds further evidence that class 
I1 molecules are dynamic entities that can occur in distinct con- 
formational states. These conformational modulations could be 
subtle, but sufficient to influence the respective binding sites. It 
would be advantageous if a conformation of ap favoring Ii binding 
were to be generated during biosynthesis, as this would facilitate 
rapid association with the trimeric Ii scaffold in the ER. Since 
CLIP has a fast off rate, it seems reasonable to assume that stabi- 
lization of the aPIi complex could be mediated by additional Ii 
contact sites recruiting flanking regions of the CLIP segment, as 
described here. These additional contact sites may also compensate 
for the poor binding of the CLIP peptide to certain class I1 alleles, 
such as  DR4  (34) (H. Kropshofer, A. Vogt, and G. J. Hammerling, 
unpublished observations) or Ak (47). 
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